The Study
Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: A meta-analysis.
This study looks at results from 13 other studies and combines them to see which cholesterol treatment works better. It shows that one combo treatment is linked to better cholesterol numbers, but we can't say for sure it caused the improvement because we don’t know if the original studies were fair tests with random assignment.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
The study looks at two ways to treat high cholesterol in heart disease patients: one uses a strong statin alone, the other uses a medium-strength statin with another drug called ezetimibe.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 539 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The combo works a bit better at lowering cholesterol, and isn't riskier for side effects, which could help patients reach heart health goals.
- 2More patients reached the cholesterol goal with the combo (odds ratio 1.76).
- 3The combo lowered LDL by 5.05 mg/dL more, and also reduced total cholesterol and triglycerides more.
- 4Side effects were about the same.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of clinical lipidology
Year
2024
Authors
F. Kelly, F. C. A. de Moraes, A. Lôbo, V. M. Siebel, M. Leite, A. D. de Almeida, F. Consolim-Colombo
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.